Peplin into Phase III
Tuesday, 09 September, 2008
Peplin [ASX: PLI] has begun a Phase III trial of its PEP005 gel for solar keratoses, common pre-cancerous skin lesions.
The trial will examine the efficacy of the gel when applied to locations other than the head. It will be simultaneously conducted in sites in Australia and the US.
The trial is being conducted with a Special Protocol Assessment from the US FDA, which ensures that the results of the study may be submitted to the FDA as part of the basis of a new drug application.
Around 250 participants are expected take part in the trial of PEP005, an ingenol mebutate gel.
Researchers genetically engineer snake antivenom
An international team of researchers has used genetic engineering to create so-called...
Common medications linked to adverse breast cancer outcomes
An international study has found concerning evidence about the impact of a range of common...
Saliva-based biosensor could improve heart failure detection
Scientists have created a biosensor that can rapidly detect the heart failure biomarker S100A7 in...
